SCHEMBL4617591

SCHEMBL4617591

COc1ccc(CCNS(=O)(=O)c2cc(S(=O)(=O)c3ccc(F)cc3)ccc2C)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.72
SFRP1 Q8N474 2/20 0.65
SMN1; SMN2 Q16637 4/20 0.62
POLB P06746 2/20 0.55
AKR1C3 P42330 1/20 0.49
TAAR1 Q96RJ0 1/20 0.49
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
KMT2A Q03164 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA5A P35218 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4618887 0.92 SFRP1 (0.75) ALDH1A1SFRP1SMN1; SMN2POLBTAAR1
SCHEMBL4616336 0.91 SFRP1 (0.61) ALDH1A1SFRP1SMN1; SMN2POLBTAAR1
SCHEMBL4617536 0.91 SFRP1 (0.67) ALDH1A1SFRP1SMN1; SMN2POLBAKR1C3
SCHEMBL4618783 0.90 SFRP1 (0.80) ALDH1A1SFRP1SMN1; SMN2POLBAKR1C3
SCHEMBL4618872 0.89 SFRP1 (0.62) ALDH1A1SFRP1SMN1; SMN2POLBTAAR1
SCHEMBL4617469 0.89 SFRP1 (0.65) ALDH1A1SFRP1SMN1; SMN2POLBAKR1C3
SCHEMBL4617440 0.89 ALDH1A1 (0.58) ALDH1A1SFRP1SMN1; SMN2MAPTTP53
SCHEMBL4617746 0.89 SFRP1 (0.70) ALDH1A1SFRP1POLBAKR1C3TAAR1
SCHEMBL4619649 0.89 SFRP1 (0.70) ALDH1A1SFRP1POLBAKR1C3TAAR1
SCHEMBL6100257 0.89 SFRP1 (0.64) ALDH1A1SFRP1SMN1; SMN2POLBAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 ALDH1A1 1865/4885SFRP1 1/4885SMN1; SMN2 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.